Merkel Cell Carcinoma Treatment Market To Reach USD 4.3 Billion By 2032 | DataHorizzon Research
11 mai 2024 03h40 HE
|
DataHorizzon Research
Fort Collins, Colorado, May 11, 2024 (GLOBE NEWSWIRE) -- The rise in skin disorders aggravates the need for merkel cell carcinoma treatment industry. The merkel cell carcinoma treatment market is...
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h15 HE
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
09 mai 2024 16h05 HE
|
Sensus Healthcare, Inc.
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year...
Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
09 mai 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
SkinCure Oncology’s GentleCure™ Experience to be Featured in National Public Health PSA Series
08 mai 2024 09h00 HE
|
SkinCure Oncology LLC
GentleCure will be recognized as an innovative healthcare technology in an upcoming public service announcement (PSA) about nonmelanoma skin cancer.
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
07 mai 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
07 mai 2024 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
06 mai 2024 08h00 HE
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.